{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T01:02:03Z","timestamp":1784509323334,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To highlight tranexamic acid (TXA) as \u2018just one thing\u2019 that every hospital could implement to reduce surgical bleeding and blood transfusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>TXA is a low\u2010cost antifibrinolytic agent that inhibits the breakdown of fibrin blood clots. Developed in Japan in the 1960s, it has been shown to reduce surgical bleeding. TXA is also effective in traumatic and postpartum haemorrhage, with no proven increase in thrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Evidence from clinical trials, national guidelines, and policy reports was reviewed, including NICE recommendations and the UK Infected Blood Inquiry report. Patterns of TXA use and barriers to implementation were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There is strong evidence for the safety and effectiveness of TXA in surgery. However, despite inclusion in NICE guidelines since 2016, approximately one quarter of eligible surgical patients in the UK do not receive TXA, with similar underuse reported internationally. This results in missed opportunities to improve patient outcomes and reduce costs. The UK Infected Blood Inquiry recommended inclusion of TXA on surgical checklists, supported by regular audit and reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TXA represents an effective intervention to improve surgical outcomes and reduce transfusion. Increased uptake requires stronger leadership, audit systems, training, patient advocacy and alignment of clinical incentives with evidence\u2010based practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tme.70101","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:19:30Z","timestamp":1784506770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Just one thing to reduce bleeding: Put tranexamic acid on the safe surgical checklist at your hospital"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-6054","authenticated-orcid":false,"given":"Ian","family":"Roberts","sequence":"first","affiliation":[{"name":"Clinical Trials Unit London School of Hygiene and Tropical Medicine  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1514-5005","authenticated-orcid":false,"given":"Katharine","family":"Ker","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit London School of Hygiene and Tropical Medicine  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2302\/kjm.11.105","article-title":"Amino\u2010methyl\u2010cyclohexane\u2010carbolic acid: AMCHA. A new potent inhibitor of fibrinolysis","volume":"11","author":"Okamoto S","year":"1962","journal-title":"Keio J Med"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075720","article-title":"Efficacy and safety of tranexamic acid in acute haemorrhage","volume":"384","author":"Franchini M","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0884","article-title":"Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta\u2010analysis, and meta\u2010regression","volume":"156","author":"Taeuber I","year":"2021","journal-title":"JAMA Surg"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13054-021-03799-9","article-title":"Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta\u2010analysis","volume":"25","author":"Murao S","year":"2021","journal-title":"Crit Care"},{"issue":"2","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0038-1648410","article-title":"Type I congenital plasminogen deficiency is not a risk factor for thrombosis","volume":"67","author":"Shigekiyo T","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH\u20102): a randomised, placebo\u2010controlled trial","volume":"376","author":"The CRASH\u20102 Trial Collaborators","year":"2010","journal-title":"Lancet"},{"issue":"10084","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post\u2010partum haemorrhage (WOMAN): an international, randomised, double\u2010blind, placebo\u2010controlled trial","volume":"389","author":"WOMAN trial collaborators","year":"2017","journal-title":"Lancet"},{"issue":"10241","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high\u2010dose 24\u2010h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT\u2010IT): an international randomised, double\u2010blind, placebo\u2010controlled trial","volume":"395","author":"HALT\u2010IT trial collaborators","year":"2020","journal-title":"Lancet"},{"issue":"10210","key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(19)32233-0","article-title":"Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH\u20103): a randomised, placebo\u2010controlled trial","volume":"394","author":"CRASH\u20103 Trial Collaborators","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2215457","article-title":"Prehospital tranexamic acid for severe trauma","volume":"389","author":"PATCH\u2010Trauma Investigators and the ANZICS Clinical Trials Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.2020.8958","article-title":"Effect of out\u2010of\u2010hospital tranexamic acid vs placebo on 6\u2010month functional neurologic outcomes in patients with moderate or severe traumatic brain injury","volume":"324","author":"Rowell SE","year":"2020","journal-title":"JAMA"},{"issue":"10463","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(24)01749-5","article-title":"The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN\u20102): an international, randomised, double\u2010blind, placebo\u2010controlled trial","volume":"404","author":"WOMAN\u20102 Trial Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMoa2207419","article-title":"Eunice kennedy shriver national institute of child health and human development maternal\u2013fetal medicine units network. Tranexamic acid to prevent obstetrical hemorrhage after cesarean delivery","volume":"388","author":"Pacheco LD","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary\u2010artery surgery","volume":"376","author":"Myles PS","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","article-title":"POISE\u20103 Investigators. Tranexamic acid in patients undergoing noncardiac surgery","volume":"386","author":"Devereaux PJ","year":"2022","journal-title":"N Engl J Med"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta\u2010analysis","volume":"344","author":"Ker K","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/bjs.9193","article-title":"Systematic review, meta\u2010analysis and meta\u2010regression of the effect of tranexamic acid on surgical blood loss","volume":"100","author":"Ker K","year":"2013","journal-title":"Br J Surg"},{"key":"e_1_2_9_19_1","unstructured":"NHSB&T.National comparative audit of NICE quality standard QS138.2024Accessed March 2025.https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco\u2010assets\u2010corp\/36009\/2024\u2010nice\u2010qs138\u2010audit\u2010report.pdf"},{"key":"e_1_2_9_20_1","unstructured":"NICE.Blood transfusion \u2013 guideline. Draft for consultation. Accessed November 2025.https:\/\/www.nice.org.uk\/guidance\/gid-ng10441\/documents\/450-2"},{"key":"e_1_2_9_21_1","unstructured":"NICE.Blood transfusion quality standard QS138.2016. Accessed 2 July 2026.https:\/\/www.nice.org.uk\/guidance\/qs138"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X18811977"},{"issue":"4","key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/tme.12780","article-title":"Prophylactic tranexamic acid use in non\u2010cardiac surgeries at high risk for transfusion","volume":"31","author":"Houston BL","year":"2021","journal-title":"Transfus Med"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/gpm-22-12","article-title":"A survey of gynecologists' utilization of tranexamic acid and factors influencing prophylactic use of tranexamic acid","volume":"6","author":"Bogue R","year":"2023","journal-title":"Gynecol Pelvic Med"},{"issue":"5","key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jse.2024.08.051","article-title":"Tranexamic acid use in total shoulder arthroplasty continues to increase and is safe in high\u2010risk patients","volume":"34","author":"Mayfield CK","year":"2025","journal-title":"J Shoulder Elbow Surg"},{"issue":"3","key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5114\/ait.2024.142670","article-title":"Perioperative utilization of tranexamic acid in total knee and hip arthroplasty procedures in Poland \u2013 a survey\u2010based study","volume":"56","author":"Studzi\u0144ska D","year":"2024","journal-title":"Anaesthesiol Intensive Ther"},{"key":"e_1_2_9_27_1","unstructured":"Infected Blood Inquiry.The report: overview and recommendations.2024. Accessed 2 July 2026.https:\/\/www.infectedbloodinquiry.org.uk\/reports\/inquiry-report"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.70101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tme.70101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.70101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:19:40Z","timestamp":1784506780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.70101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":26,"alternative-id":["10.1111\/tme.70101"],"URL":"https:\/\/doi.org\/10.1111\/tme.70101","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"2025-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"tme.70101"}}